Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: A pilot study

Clinical Drug Investigation

Volumn 27, Issue 9, 2007, Pages 605-611

  Darwish, Mona ^a   Kirby, Mary ^a   Robertson, Philmore ^a   Tracewell, William ^a   Jiang, John G ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; FENTORA; MORPHINE; OPIATE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG ABSORPTION; DRUG TOLERABILITY; EFFERVESCENT TABLET; FEMALE; HUMAN; MALE; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TABLET FORMULATION;

ABSORPTION; ADMINISTRATION, BUCCAL; ADULT; AGED; ANALGESICS, OPIOID; ANTINEOPLASTIC AGENTS; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PENNSYLVANIA; PILOT PROJECTS; RADIOTHERAPY; SEVERITY OF ILLNESS INDEX; STOMATITIS; TABLETS;

EID: 34548077818     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727090-00002     Document Type: Article

References (16)

1. Lesage P, Portenoy RK. Trends in cancer pain management. Cancer Control 1999; 6: 136-45
2. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999; 81: 129-34
3. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1: Assessment. Pharm Ther 2005; 30: 296-301
4. Kwong KKF. Prevention and treatment of oropharyngeal mucositis following cancer therapy: are there new approaches? Cancer Nurs 2004; 27: 183-205
5. Borbasi S, Cameron K, Quested B, et al. More than a sore mouth: patients' experience of oral mucositis. Oncol Nurs Forum 2002; 29: 1051-7
6. Berger A, Henderson M, Nadoolman W, et al. Oral capsaicin provides temporary relief for oral mucositis pain secondary to chemotherapy/radiation therapy. J Pain Symptom Manage 1995; 10: 243-8
7. Ohrn KEO, Wahlin YB, Sjoden PO. Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of oral complications. Support Care Cancer 2001; 9: 247-57
8. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998; 34: 39-43
9. Wardley AM, Jayson GC, Swidnell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000; 110: 292-9
10. Berger AM, Eilers J. Factors influencing oral cavity status during high-dose antineoplastic therapy: a secondary data analysis. Oncol Nurs Forum 1998; 25: 1623-6
11. Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006; 22: 805-11
12. Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Deliv 2006; 4: 1-5
13. CTCAE. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. Publication date: 2006 Aug 9 [online]. Available from URL: http://ctep.cancer.gov [Accessed 2006 Dec 14]
14. Darwish M, Kirby M, Robertson Jr P, et al. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 μg in healthy adult volunteers. Clin Ther 2006; 28: 707-14
15. Gibaldi M, Perrier D. Pharmacokinetics, chapter 11. 2nd edition. New York: Marcel Dekker, 1982
16. Darwish M, Tempero K, Kirby M, et al. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet 2005; 44: 1279-86